Cancer in human immunodeficiency virus-infected children

A case series from the Children's Cancer Group and the National Cancer Institute

Monica O. Granovsky, Brigitta U. Mueller, H. Stacy Nicholson, Philip S. Rosenberg, Charles S. Rabkin

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Purpose: To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors. Methods: We retrospectively surveyed the Children's Cancer Group (CCG) and the National Cancer Institute (NCI) for cases of cancer that occurred between July 1982 and February 1997 in children who were HIV seropositive before or at the time of cancer diagnosis. We used Kaplan-Meier survivorship curves, hazard function estimates, and Cox proportional hazards models to evaluate survival. Results: Sixty-four children (39 boys, 25 girls) with 65 tumors were reported. Thirty-seven children (58%) acquired HIV infection vertically (median age at cancer diagnosis, 4.3 years); 22 children (34%) acquired HIV through transfusion of blood at blood products (median age at cancer diagnosis, 13.4 years). Forty- two children (65%) had non-Hodgkin's lymphoma (NHL). Eleven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exceptionally rare in children. Other malignancies included acute leukemia (five children), Kaposi's sarcoma (KS; three children), Hodgkin's disease (two children), vaginal carcinoma in situ (one child), and tracheal neuroendocrine carcinoma (one child). Median survival after NHL diagnosis was 6 months (range, 1 day to 89 months) and after leiomyosarcoma was 12 months (range, 10 days to 19 months). The average monthly death rate after NHL diagnosis was 12% in the first 6 months, which decreased to about 2% thereafter. In contrast, the monthly death rate after leiomyosarcoma diagnosis increased from 5% in the first 6 months to about 20% thereafter. Conclusion: After NHL, leiomyosarcoma is the second leading cancer in children with HIV infection. Both cancers have high mortality rates; improved outcome for NHL, in particular, may depend on earlier diagnosis and therapy.

Original languageEnglish (US)
Pages (from-to)1729-1735
Number of pages7
JournalJournal of Clinical Oncology
Volume16
Issue number5
StatePublished - May 1998
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
HIV
Neoplasms
Non-Hodgkin's Lymphoma
Leiomyosarcoma
Virus Diseases
Mortality
Neuroendocrine Carcinoma
Survival
Second Primary Neoplasms
Kaposi's Sarcoma
Carcinoma in Situ
Leiomyoma
Secondary Prevention
Hodgkin Disease
Proportional Hazards Models
Blood Transfusion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Granovsky, M. O., Mueller, B. U., Nicholson, H. S., Rosenberg, P. S., & Rabkin, C. S. (1998). Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute. Journal of Clinical Oncology, 16(5), 1729-1735.

Cancer in human immunodeficiency virus-infected children : A case series from the Children's Cancer Group and the National Cancer Institute. / Granovsky, Monica O.; Mueller, Brigitta U.; Nicholson, H. Stacy; Rosenberg, Philip S.; Rabkin, Charles S.

In: Journal of Clinical Oncology, Vol. 16, No. 5, 05.1998, p. 1729-1735.

Research output: Contribution to journalArticle

Granovsky, MO, Mueller, BU, Nicholson, HS, Rosenberg, PS & Rabkin, CS 1998, 'Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute', Journal of Clinical Oncology, vol. 16, no. 5, pp. 1729-1735.
Granovsky, Monica O. ; Mueller, Brigitta U. ; Nicholson, H. Stacy ; Rosenberg, Philip S. ; Rabkin, Charles S. / Cancer in human immunodeficiency virus-infected children : A case series from the Children's Cancer Group and the National Cancer Institute. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 5. pp. 1729-1735.
@article{e90410340d524ac08ac8caa592bd6bec,
title = "Cancer in human immunodeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute",
abstract = "Purpose: To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors. Methods: We retrospectively surveyed the Children's Cancer Group (CCG) and the National Cancer Institute (NCI) for cases of cancer that occurred between July 1982 and February 1997 in children who were HIV seropositive before or at the time of cancer diagnosis. We used Kaplan-Meier survivorship curves, hazard function estimates, and Cox proportional hazards models to evaluate survival. Results: Sixty-four children (39 boys, 25 girls) with 65 tumors were reported. Thirty-seven children (58{\%}) acquired HIV infection vertically (median age at cancer diagnosis, 4.3 years); 22 children (34{\%}) acquired HIV through transfusion of blood at blood products (median age at cancer diagnosis, 13.4 years). Forty- two children (65{\%}) had non-Hodgkin's lymphoma (NHL). Eleven children (17{\%}) had leiomyosarcomas (or leiomyomas), which are otherwise exceptionally rare in children. Other malignancies included acute leukemia (five children), Kaposi's sarcoma (KS; three children), Hodgkin's disease (two children), vaginal carcinoma in situ (one child), and tracheal neuroendocrine carcinoma (one child). Median survival after NHL diagnosis was 6 months (range, 1 day to 89 months) and after leiomyosarcoma was 12 months (range, 10 days to 19 months). The average monthly death rate after NHL diagnosis was 12{\%} in the first 6 months, which decreased to about 2{\%} thereafter. In contrast, the monthly death rate after leiomyosarcoma diagnosis increased from 5{\%} in the first 6 months to about 20{\%} thereafter. Conclusion: After NHL, leiomyosarcoma is the second leading cancer in children with HIV infection. Both cancers have high mortality rates; improved outcome for NHL, in particular, may depend on earlier diagnosis and therapy.",
author = "Granovsky, {Monica O.} and Mueller, {Brigitta U.} and Nicholson, {H. Stacy} and Rosenberg, {Philip S.} and Rabkin, {Charles S.}",
year = "1998",
month = "5",
language = "English (US)",
volume = "16",
pages = "1729--1735",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Cancer in human immunodeficiency virus-infected children

T2 - A case series from the Children's Cancer Group and the National Cancer Institute

AU - Granovsky, Monica O.

AU - Mueller, Brigitta U.

AU - Nicholson, H. Stacy

AU - Rosenberg, Philip S.

AU - Rabkin, Charles S.

PY - 1998/5

Y1 - 1998/5

N2 - Purpose: To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors. Methods: We retrospectively surveyed the Children's Cancer Group (CCG) and the National Cancer Institute (NCI) for cases of cancer that occurred between July 1982 and February 1997 in children who were HIV seropositive before or at the time of cancer diagnosis. We used Kaplan-Meier survivorship curves, hazard function estimates, and Cox proportional hazards models to evaluate survival. Results: Sixty-four children (39 boys, 25 girls) with 65 tumors were reported. Thirty-seven children (58%) acquired HIV infection vertically (median age at cancer diagnosis, 4.3 years); 22 children (34%) acquired HIV through transfusion of blood at blood products (median age at cancer diagnosis, 13.4 years). Forty- two children (65%) had non-Hodgkin's lymphoma (NHL). Eleven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exceptionally rare in children. Other malignancies included acute leukemia (five children), Kaposi's sarcoma (KS; three children), Hodgkin's disease (two children), vaginal carcinoma in situ (one child), and tracheal neuroendocrine carcinoma (one child). Median survival after NHL diagnosis was 6 months (range, 1 day to 89 months) and after leiomyosarcoma was 12 months (range, 10 days to 19 months). The average monthly death rate after NHL diagnosis was 12% in the first 6 months, which decreased to about 2% thereafter. In contrast, the monthly death rate after leiomyosarcoma diagnosis increased from 5% in the first 6 months to about 20% thereafter. Conclusion: After NHL, leiomyosarcoma is the second leading cancer in children with HIV infection. Both cancers have high mortality rates; improved outcome for NHL, in particular, may depend on earlier diagnosis and therapy.

AB - Purpose: To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors. Methods: We retrospectively surveyed the Children's Cancer Group (CCG) and the National Cancer Institute (NCI) for cases of cancer that occurred between July 1982 and February 1997 in children who were HIV seropositive before or at the time of cancer diagnosis. We used Kaplan-Meier survivorship curves, hazard function estimates, and Cox proportional hazards models to evaluate survival. Results: Sixty-four children (39 boys, 25 girls) with 65 tumors were reported. Thirty-seven children (58%) acquired HIV infection vertically (median age at cancer diagnosis, 4.3 years); 22 children (34%) acquired HIV through transfusion of blood at blood products (median age at cancer diagnosis, 13.4 years). Forty- two children (65%) had non-Hodgkin's lymphoma (NHL). Eleven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exceptionally rare in children. Other malignancies included acute leukemia (five children), Kaposi's sarcoma (KS; three children), Hodgkin's disease (two children), vaginal carcinoma in situ (one child), and tracheal neuroendocrine carcinoma (one child). Median survival after NHL diagnosis was 6 months (range, 1 day to 89 months) and after leiomyosarcoma was 12 months (range, 10 days to 19 months). The average monthly death rate after NHL diagnosis was 12% in the first 6 months, which decreased to about 2% thereafter. In contrast, the monthly death rate after leiomyosarcoma diagnosis increased from 5% in the first 6 months to about 20% thereafter. Conclusion: After NHL, leiomyosarcoma is the second leading cancer in children with HIV infection. Both cancers have high mortality rates; improved outcome for NHL, in particular, may depend on earlier diagnosis and therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031804710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031804710&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1729

EP - 1735

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -